data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Royalty Pharma

(NASDAQ:RPRX)

Intraday

$28.00

-0.11[-0.39%]

After-Hours

$28.00

0[0.00%]

Perks Buy Compare Brokers

$28.00

-0.11[-0.39%]

At close: Apr 26

$28.00

0[0.00%]

After Hours: 4:20PM EDT

Q1 2024 Earnings in 11 days from now on Thu May 9th, before the market open

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Royalty Pharma Stock (NASDAQ:RPRX)

Royalty Pharma Stock (NASDAQ: RPRX)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, April 12, 2024

B of A Securities Maintains Buy on Royalty Pharma, Lowers Price Target to $38
Benzinga Newsdesk - Apr 12, 2024, 8:01AM

Thursday, April 04, 2024

Looking Into Royalty Pharma's Recent Short Interest
Benzinga Insights - Apr 4, 2024, 11:15AM

Thursday, February 15, 2024

Royalty Pharma Q4 Sales $596.00M Miss $673.65M Estimate, Net Income Attributable To Royalty Pharma $494M Versus Loss Of $(456)M Year Ago
Benzinga Newsdesk - Feb 15, 2024, 7:34AM
Earnings Scheduled For February 15, 2024
Benzinga Insights - Feb 15, 2024, 5:17AM

Wednesday, February 14, 2024

Royalty Pharma's Earnings: A Preview
Benzinga Insights - Feb 14, 2024, 9:00AM

Friday, January 19, 2024

CORRECTION: Royalty Pharma Announces Quarterly Dividend Increase From $0.20 To $0.21
Benzinga Newsdesk - Jan 19, 2024, 8:23AM
Royalty Pharma Announces Quarterly Dividend Increase From $0.20 To $0.21
Benzinga Newsdesk - Jan 19, 2024, 8:16AM

Wednesday, January 17, 2024

Watching MSCI Inc.; Spruce Point Capital Management Announces Investment Opinion Entitled "Indexing The Short Case Against MSCI"; Says The Co Could Face Up To 55%-65% Long-Term Downside Risk, Or $190.00–$244.00 Per Share
Benzinga Newsdesk - Jan 17, 2024, 9:39AM

Monday, January 08, 2024

Royalty Pharma Expects To Deliver Portfolio Receipts For FY23 Of Approximately $3.05B, Which Includes A $50M Payment Related To Oral Zavegepant And Exceeds The Upper End Of Its Previous Guidance Range Of $2.95B-$3B
Benzinga Newsdesk - Jan 8, 2024, 7:35AM

Monday, November 13, 2023

Teva And Royalty Pharma Announce Collaboration To Further Accelerate Olanzapine LAI Program; Royalty To Provide R&D Funding Support Of Up To $125M For Development Of Olanzapine LAI
Benzinga Newsdesk - Nov 13, 2023, 8:12AM

Thursday, November 09, 2023

Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $57
Benzinga Newsdesk - Nov 9, 2023, 9:37AM

Wednesday, November 08, 2023

Royalty Pharma Sees FY23 Adj. Cash Receipts $2.95B-$3B
Benzinga Newsdesk - Nov 8, 2023, 7:04AM
Royalty Pharma Q3 2023 EPS Adj. Cash Receipts $637M May Not Compare To $617.989M Estimate
Benzinga Newsdesk - Nov 8, 2023, 7:03AM
Earnings Scheduled For November 8, 2023
Benzinga Insights - Nov 8, 2023, 4:21AM

Tuesday, November 07, 2023

Royalty Pharma's Earnings Outlook
Benzinga Insights - Nov 7, 2023, 9:01AM

Thursday, October 19, 2023

PTC Therapeutics Announced An Agreement With Royalty Pharma To Monetize Up To $1.5B Of The Evrysdi Royalty Stream. Under The Agreement, Royalty Pharma Acquires Additional Royalties On Evrysdi For $1B Upfront
Benzinga Newsdesk - Oct 19, 2023, 8:07AM

Wednesday, October 11, 2023

Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $54
Benzinga Newsdesk - Oct 11, 2023, 10:51AM

Thursday, September 21, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Sep 21, 2023, 12:08PM

Tuesday, September 19, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Sep 19, 2023, 12:50PM

Friday, September 15, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 15, 2023, 11:52AM

Thursday, September 07, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Sep 7, 2023, 1:55PM

Tuesday, September 05, 2023

Ascendis Pharma And Royalty Pharma Enter Into $150M Royalty Funding Agreement; Proceeds To Support Continued Development And Commercialization Of Endocrine Rare Disease Products, And General Corporate Purposes
Happy Mohamed - Sep 5, 2023, 4:03PM

Thursday, August 24, 2023

Royalty Pharma Pens $500M Royalty Agreement With Ferring Pharmaceuticals For New Intravesical Gene Therapy Adstiladrin® (nadofaragene Firadenovec-vncg)
Benzinga Newsdesk - Aug 24, 2023, 6:33AM
Royalty Pharma And Ferring Pharmaceuticals Ink $500M Royalty Deal For Innovative Intravesical Gene Therapy Adstiladrin
Benzinga Newsdesk - Aug 24, 2023, 2:54AM

Wednesday, August 09, 2023

Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $53
Benzinga Newsdesk - Aug 9, 2023, 10:56AM

Tuesday, August 08, 2023

Royalty Pharma Sees FY23 Adjusted Cash Receipts (non-GAAP) To Be $2.90B-$2.975B (Prior Guidance: $2.850B-$2.950B)
Benzinga Newsdesk - Aug 8, 2023, 7:15AM
Royalty Pharma Q2 Adj EPS $0.84 Beats $0.83 Estimate, Sales $538.00M Miss $538.52M Estimate
Benzinga Newsdesk - Aug 8, 2023, 7:10AM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Tuesday, July 11, 2023

Morgan Stanley Reiterates Overweight on Royalty Pharma, Maintains $52 Price Target
Benzinga Newsdesk - Jul 11, 2023, 9:43AM

Thursday, June 29, 2023

Royalty Pharma CEO Trades Company's Stock
Benzinga Insights - Jun 29, 2023, 11:06AM
$122M Bet On Occidental Petroleum? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin - Jun 29, 2023, 8:50AM

Friday, June 16, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Jun 16, 2023, 1:08PM

Thursday, June 15, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Jun 15, 2023, 2:53PM

Wednesday, June 14, 2023

$10M Bet On GameStop? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin - Jun 14, 2023, 9:11AM

Wednesday, June 07, 2023

Royalty Pharma EVP Sold $6.48M In Company Stock
Benzinga Insights - Jun 7, 2023, 11:08AM

Thursday, May 25, 2023

CEO of Royalty Pharma Makes $4.84M Buy
Benzinga Insights - May 25, 2023, 11:03AM

Wednesday, May 24, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - May 24, 2023, 12:49PM

Thursday, May 18, 2023

Royalty Pharma CEO Makes $7.68M Stock Purchase
Benzinga Insights - May 18, 2023, 11:03AM
$12.5M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying
Lisa Levin - May 18, 2023, 9:18AM

Wednesday, May 10, 2023

Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $52
Benzinga Newsdesk - May 10, 2023, 8:11AM

Tuesday, May 09, 2023

Royalty Pharma shares are trading lower after the company reported mixed Q1 financial results.
Benzinga Newsdesk - May 9, 2023, 1:47PM
Balance Sheet Showdown
GRIT Capital - May 9, 2023, 1:25PM
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
Lekha Gupta - May 9, 2023, 11:15AM
Royalty Pharma Q1 EPS $1.60 Beats $1.27 Estimate, Sales $684.00M Miss $852.90M Estimate
Benzinga Newsdesk - May 9, 2023, 7:18AM
Earnings Scheduled For May 9, 2023
Benzinga Insights - May 9, 2023, 6:03AM

Monday, May 08, 2023

Earnings Outlook For Royalty Pharma
Benzinga Insights - May 8, 2023, 10:01AM

Monday, April 10, 2023

Tigress Financial Reiterates Buy on Royalty Pharma, Raises Price Target to $60
Benzinga Newsdesk - Apr 10, 2023, 10:28AM
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $50
Benzinga Newsdesk - Apr 10, 2023, 10:25AM

Monday, March 27, 2023

Royalty Pharma shares are trading higher after the company authorized a share repurchase program of up to $1 billion.
Michael Horton - Mar 27, 2023, 10:13AM
Royalty Pharma Plans $1B Share Repurchase Program
Benzinga Newsdesk - Mar 27, 2023, 7:31AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved